
|Articles|October 24, 2012
Investigative therapy for melanoma promising
An investigative combination therapy combining chemotherapy and immunotherapy of adoptive cell transfer with tumor infiltrating lymphocytes, followed by interleukin-2, is labor-intensive but a feasible therapy with a high response rate in treated patients, according to researchers.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















